As a world leader in antibody production, ProteoGenix strives to offer the best of antibody production to its customers. Our wish is to link the most ambitious and innovative antibody production projects with our highly skilled and passionate team of experts. Our expertise and state-of-the-art technologies coupled with the enthusiasm we daily put in succeeding in your projects explains our unrivalled track record.
Our antibody production services
Choose our unique phage display guaranteed service. Phage display is highly relevant for therapeutic monoclonal antibody development. It offers several advantages such as the possibility to screen directly a wide range of libraries (llama, rabbit…) including human libraries and avoids animal use.
Thanks to a success rate of over 98% on more than 1500 antibodies projects, ProteoGenix is able to offer the strongest guarantees on the market for hybridoma development. Our application guaranteed packages even include the sending of a test sample to confirm that the antibodies work in your own lab before releasing full payment!
ProteoGenix developed XtenCHOTM, the most productive expression system for transient monoclonal antibody production. Thanks to its outstanding performances, get your purified antibodies starting from 730€!
Get access to more than 28 years of expertise in affinity maturation with ProteoGenix! Our affinity maturation services by phage display is all inclusive from library construction to antibody expression and tests.
Choose a partner having more than 15 years of experience in high-quality polyclonal antibody production. ProteoGenix offers one-stop solution from antigen design to purified polyclonal antibody delivery.
You can even order only thanks to our entertaining interactive form!
Get the most productive IP free stable cell line on the market! Our stable cell line development service based on our proprietary cell line aims at offering high productivity at competitive price and FTO without royalties!
ProteoGenix developed high-class DNA immunization services to overcome the barrier of difficult-to-express antigens. This technology allows polyclonal and monoclonal antibody production against the antigen in its native conformation.
As part of our antibody production services, we offer culture supernatant production and purification with serum, serum-free, or animal-free and ascites production and purification from mice.
We recommend antibody production in culture supernatant in any case.
ProteoGenix offers many types of conjugation services, such as biotin, HRP, AP (alkaline phosphatase), fluorochromes. These conjugations will be useful for most applications involving immune detection including sandwich ELISA kits
Try our tool to choose the best
antibody production technique
As a global leading antibody production company, ProteoGenix strives not only at providing best-in-class services but also a broad range of solutions to carefully adapt to each project specifications. Our passionate team is also willing to share its long-standing experience with its customers. In consequence, we developed a new interactive form to guide you to define the most relevant antibody production strategy for your project.
Why choose ProteoGenix’s custom
antibody production services?
A service adapted to your application
Our extended and unique portfolio of antibody production services allows us to propose solutions to all your challenges.
ProteoGenix is committed in animal well-being in science by applying the highest ethical standards.
Unique guarantees market
Our work is guided by customer satisfaction and explains our unrivalled success rate. It allows us to offer the highest guarantees on the
PhD account managers
We put at your disposal highly skilled account managers who guide you along your decision-making process.
Various antigen design approaches
Trust our experienced team to propose the most adapted antigen design strategy to get the most effective antibodies.
Therapeutic, diagnostic, research… As an antibody production company, ProteoGenix offers one-stop solutions to make your projects move forward!
Hybridoma or phage display for monoclonal antibody production ?
Once monoclonal antibody production is chosen, the next step is to determine which antibody generation method is the most relevant. Basically, hybridoma and phage display remain the 2 most popular technologies. The final choice will depend on several parameters.
|Direct access to sequence & recombinant antibody||No||Yes (excellent for therapeutic antibodies)|
|Potential antigen immunogenicity issue||Yes||No (naïve library only)|
|Potential clone viability issue||Yes||No|
|Animal protection||Animal injections and sacrifice||No animal use (naïve library only)|
Hybridoma technology is highly relevant for monoclonal antibody generation with high sensitivity for the target antigen. Thus, this antibody production method is the reference for assay development. Due to its lower price compared to phage display, hybridoma development represents also a good alternative for therapeutic antibody development. In this context, our hybridoma development service can be associated to our antibody humanization and affinity maturation services to get an optimized humanized antibody.
In most of cases, antibody phage display will be the preferred method for therapeutic antibody development. Phage display is based on cDNA fragments obtained from the mRNA isolated from B lymphocytes. B lymphocytes can originate from various species without any restriction, including humans. The cDNA coding for VH and VL segments can be cloned in an expression vector next to a protein of a bacteriophage (usually pIII, pVII or pVIII) before infecting E. coli. This results in large libraries (~1010) which can be screened indefinitely for new antibody generation.
Phage display for therapeutic antibody discovery offers several advantages:
- High antibody diversity depending on the size of libraries,
- Possibility to screen directly human libraries (direct access to fully human antibodies),
- Possibility to screen toxic antigens,
- Fast process including fast access to the antibody sequence and to recombinant antibody production,
- No animal use once the library is made.
Polyclonal antibody production vs.
monoclonal antibody production
When choosing between polyclonal antibodies and monoclonal antibodies, several parameters have to be taken into account. Here is an overview of advantages and drawbacks of each solution.
|Monoclonal antibodies||Polyclonal antibodies|
|Advantages||Better specificity & less background
Unlimited quantity of antibody
Standardization + repeatability
Possibility to sequence and engineer
|Potentially better immunogenicity + antibody sensitivity
Less sensitive to antigen’s conformational variations
Fast and inexpensive to produce
|Drawbacks||Potentially lesser immunogenicity + antibody sensitivity
Long and expensive to produce
|Background risk due to cross-reactions
Limited quantity of antibody
|Species available||Mouse, rat||Mouse, rat, rabbit, chicken, guinea pig, sheep, goat, alpaca, llama|
Polyclonal antibodies consist in a mixture of antibodies able to bind several epitopes of a same antigen. They are produced by animal immunization and collected directly from serum. The serum is usable as is or can be further purified in order to obtain a serum free solution. Polyclonal antibody production is less complex than monoclonal antibody production. It is therefore the best solution for a fast and inexpensive antibody development. However, polyclonal antibodies are prone to batch-to-batch variations due to the production method.
Polyclonal antibodies present several advantages due to their multiple epitope binding properties:
- they can present high sensitivity and represent a perfect solution for detection of proteins presenting a low expression level
- they are less sensitive to antigen’s conformational variations and can thus be used for denatured protein detection
However, multiple epitope binding leads to some drawbacks as it implies cross-reactivity due to lower specificity. For this reason, polyclonal antibodies are not suitable for quantitative assays or for the recognition of a specific domain. Nevertheless, several methods can limit or even overcome the cross-reactivity issue, as for example:
- immunization with one or several peptide immunogens limiting the recognition of a specific epitope,
- addition of a purification step against the target epitope.
Monoclonal antibodies are generated by identical immune cells which are clones of a single parent cell. Thus, monoclonal antibodies specifically recognize one epitope of an antigen.
First steps of monoclonal antibody generation are similar to polyclonal antibodies. Then, B lymphocytes are isolated and fused with a myeloma cell line leading to an immortalized hybridoma cell line producing the desired monoclonal antibody. Monoclonal antibody production is highly complex and is therefore more expensive than polyclonal antibody production. However, once developed, the hybridoma cell line has the ability to produce an “infinite” quantity of antibodies. Monoclonal antibody production can even be secured by hybridoma sequencing and stable cell line development
Monoclonal antibodies can present several advantages over polyclonal antibodies:
- recognition of a single epitope of an antigen,
- low cross-reactivity,
- high reproducibility,
- possibility to develop large-scale applications (therapeutic antibody development or diagnostic manufacturing).
Due to their high specificity, monoclonal antibodies are more sensitive to epitope’s conformational changes.